Literature DB >> 9236854

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.

R S Geary1, J M Leeds, S P Henry, D K Monteith, A A Levin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9236854

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN： 0266-9536


× No keyword cloud information.
  22 in total

1.  New modalities in oncology: antisense oligonucleotides.

Authors:  C Casey Cunningham
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-04

2.  Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry.

Authors:  Xiaohui Wei; Guowei Dai; Zhongfa Liu; Hao Cheng; Zhiliang Xie; Guido Marcucci; Kenneth K Chan
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

3.  Antisense oligonucleotide therapy for neurodegenerative disease.

Authors:  Richard A Smith; Timothy M Miller; Koji Yamanaka; Brett P Monia; Thomas P Condon; Gene Hung; Christian S Lobsiger; Chris M Ward; Melissa McAlonis-Downes; Hongbing Wei; Ed V Wancewicz; C Frank Bennett; Don W Cleveland
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

4.  Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don't harbor immunostimulatory properties in primary isolated liver cells.

Authors:  Catherine Isabell Real; Melanie Werner; Andreas Paul; Guido Gerken; Joerg Friedrich Schlaak; Andrew Vaillant; Ruth Broering
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

5.  Allele-Specific Inhibition of Rhodopsin With an Antisense Oligonucleotide Slows Photoreceptor Cell Degeneration.

Authors:  Susan F Murray; Ali Jazayeri; Michael T Matthes; Douglas Yasumura; Haidong Yang; Raechel Peralta; Andy Watt; Sue Freier; Gene Hung; Peter S Adamson; Shuling Guo; Brett P Monia; Matthew M LaVail; Michael L McCaleb
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

6.  A cytosine analog that confers enhanced potency to antisense oligonucleotides.

Authors:  W M Flanagan; J J Wolf; P Olson; D Grant; K Y Lin; R W Wagner; M D Matteucci
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

7.  A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.

Authors:  Ranjana Advani; Bert L Lum; George A Fisher; Joanne Halsey; Richard S Geary; Jon T Holmlund; T Jesse Kwoh; F Andrew Dorr; Branimir I Sikic
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

8.  Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.

Authors:  Angelo Corti; Monica Giovannini; Carmen Belli; Eugenio Villa
Journal:  J Oncol       Date:  2010-06-03       Impact factor: 4.375

9.  Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides.

Authors:  María González Ferreiro; Lloyd G Tillman; Gregory Hardee; Roland Bodmeier
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

10.  Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection.

Authors:  Rhonda D Cardin; Fernando J Bravo; Andrea P Sewell; James Cummins; Louis Flamand; Jean-Marc Juteau; David I Bernstein; Andrew Vaillant
Journal:  Virol J       Date:  2009-12-02       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.